Navigation Links
Cadence Pharmaceuticals Estimates Fourth Quarter and Full Year 2013 Product Revenue and Provides Full Year 2014 Revenue Guidance
Date:1/13/2014

SAN DIEGO, Jan. 13, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced preliminary (unaudited) estimates for net product revenues from sales of OFIRMEV® (acetaminophen) injection for the three months ended December 31, 2013, of approximately $33.3 million, and net product revenue for the twelve months ended December 31, 2013, of approximately $110.5 million.

"The fourth quarter and full year 2013 were exciting for Cadence as OFIRMEV sales continued to grow driven by robust demand and fueled by an increasing desire for non-narcotic analgesic options in the hospital setting," said Ted Schroeder, President and CEO of Cadence.  "We anticipate that sales of OFIRMEV will continue to increase in 2014, and expect full year 2014 net revenue for OFIRMEV to range between $173.0 million and $177.0 million."

Revenue Guidance
As of January 13, 2014, Cadence expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2014, will range between $173.0 million and $177.0 million.

Cadence will provide a more complete discussion of its financial results for the year ended December 31, 2013, during the Company's regularly scheduled quarterly conference call.

About OFIRMEV® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 4, 2013
2. Cadence Pharmaceuticals Recognized As A Top Workplace In San Diego Based On Employee Feedback
3. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
5. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
6. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
7. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
8. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
9. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
11. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014 CVS Caremark Corporation (NYSE: ... Yields and consideration payable in connection with its previously announced ... 2014 for (1) any and all of its 6.250% Senior ... up to a maximum amount of its 6.125% Senior Notes ... Notes due 2017 (collectively, the "Maximum Tender Offer Notes" and ...
(Date:8/21/2014)... 21, 2014 Professional Compounding Centers of ... by awarding the three best scientific presentations at ... conference . The Formulating Better Medicines for ... Athens, Greece , includes dozens ... professionals, from which three winners will be selected ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... THE WOODLANDS, Texas, Aug. 9, 2011 ... ), a biopharmaceutical company focused on discovering breakthrough ... data from its recently completed Phase 2 study ... etiprate. Carcinoid syndrome is a chronic condition caused ...
... SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 9, 2011 ... and Eisai Inc. announced today results from ... mammary tumor diagnoses from a two-year rat carcinogenicity study ... the lorcaserin Complete Response Letter (CRL), which questioned the ...
Cached Medicine Technology:Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 2Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 3Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 4Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 2Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 3Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 4Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 5Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study 6
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
(Date:8/21/2014)... Revista, a one-stop source for ... data, is “on a roll.” Today, the Annapolis-based ... the Southeast, Mid-Atlantic and Midwest areas of the ... widely available, comprehensive medical property database tracking these ... properties, including existing and recently added, is 34,549. ...
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 ... dropped nearly 12 percent in the last decade, a new ... of teens using indoor tanning beds barely decreased. Both indoor ... skin cancers, including deadly melanomas, the researchers noted. "Unfortunately, ... who reported wearing sunscreen, from 67.7 percent in 2001 to ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 2014 When children go back to school, ... cause them to become sick and risk missing school. It ... help them fight these germs to ensure a successful school ... just that with its XFactor program. , The XFactor program ... multi-vitamins. Children ages 4 and up can receive 30-day supplies ...
Breaking Medicine News(10 mins):Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:MedX Pharmacy Helps with Back to School Preparation 2
... Calif. - A single dose of antibiotics can significantly ... vaginal tissues during many births, according to researchers at ... School of Medicine and Santa Clara Valley Medical Center. ... simple treatment can prevent many of the short- and ...
... Mylan Inc. (NYSE: MYL ),today announced that ... U.S. Food and Drug Administration (FDA) for its,Abbreviated New ... 10,mg., Zaleplon Capsules are the generic version of ... $88 million for,the 12 months ending March 31, 2008, ...
... handful of measures are,effective, NEWTOWN, Conn., June ... and policy makers about the importance of choosing,the ... measurement,efforts, Bridges to Excellence(TM) (BTE) conducted a review ... physicians meet certain ambulatory,care quality measures. The study, ...
... Company donates $100,000 to American Red Cross, INDIANAPOLIS, ... arm of Eli Lilly and Company (NYSE: LLY ... assistance to aid,Indiana tornado and flood victims. More than ... Gov. Mitch Daniels as a result of deadly,tornadoes and ...
... Va., June 9 The National,Community Pharmacists ... Pharmacists (IACP) are collaborating to increase the,legislative ... in compounding.,IACP has established a satellite office ... Director of Public Affairs, Sarah R. Dodge. ...
... N.J., June 9 Wyeth (NYSE: WYE ... Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on June ... Wyeth will be Bernard Poussot, President and Chief,Executive ... live for investors at, http://www.wyeth.com and available ...
Cached Medicine News:Health News:Antibiotics can prevent wound complications of childbirth, Stanford/Packard study finds 2Health News:Bridges to Excellence Study Assesses Clinical and Financial Impact of Physician Quality Measures 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2
... plate acc. to Matzen is used for ... (HWS) with the exception of C0-C2. The ... fusion length until the bone transplant has ... the vertebral bodies, if possible along the ...
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
Medicine Products: